4 completed, 2 recruiting, 1 unknown. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 4, Recruiting 2, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Thymalfasin: new trials by email Literature Review of Thymalfasin trials Research Report on Thymalfasin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thymosin-α1 for Recurrent Implantation Failure Thymosin Alpha1, Placebo Control - Recurrent Implantation Faliure | Phase 2 / Phase 3 | Recruiting | Fakih IVF Fertility Center | 136 | 2026-02-11 | 2026-10-15 |
| Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer Thymosin Alpha1 - Stage II Colorectal Cancer, Stage III Colorectal Cancer | Phase 3 | Recruiting | Fudan University | 2500 | 2021-04-01 | 2021-10-21 |
| Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff recombinant human interferon Alpha-1b, thymosin alpha 1 - 2019 Novel Coronavirus Infection | Phase 3 | Unknown | Shanghai Jiao Tong University School of Medicine | 2944 | 2020-01-21 | 2020-03-31 |
| The Efficacy and Safety of Ta1 for Sepsis Thymosin alpha 1, Placebo - Sepsis | Phase 3 | Completed | Sun Yat-sen University | 1106 | 2016-09-06 | 2023-04-10 |
| Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin. Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a - Chronic Hepatitis C | Phase 3 | Completed | sigma-tau i.f.r. S.p.A. | 552 | 2004-12-01 | 2010-08-10 |
| Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a - Hepatitis C, Hepatitis C, Chronic | Phase 3 | Completed | SciClone Pharmaceuticals | 500 | 2002-05-01 | 2008-01-15 |
| Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a - Hepatitis C, Hepatitis C, Chronic | Phase 3 | Completed | SciClone Pharmaceuticals | 500 | 2002-04-01 | 2008-01-15 |
Hepatitis C, Chronic (3) · Hepatitis C (2) · COVID-19 (1) · Colorectal Neoplasms (1) · Liver Cirrhosis (1) · Sepsis (1)
SciClone Pharmaceuticals (2) · Fakih IVF Fertility Center (1) · Fudan University (1) · Shanghai Jiao Tong University School of Medicine (1) · Sun Yat-sen University (1) · sigma-tau i.f.r. S.p.A. (1)
China (3) · Puerto Rico (2) · United States (2) · France (1) · Germany (1) · Greece (1) · Italy (1) · Spain (1) · United Arab Emirates (1)
Guan Xiangdong, M. D (1) · Mario Rizzetto, MD (1) · Michael Fakih, MD (1)
PMID 17495242, PMID 20549321, PMID 22233415, PMID 23045964, PMID 23327199, PMID 39814420, PMID 42164588
2004 (1)